People with higher-risk myelodysplastic syndrome who received pevonedistat and azacitidine had improved event-free survival and a trend toward overall survival improvement, compared with those who were given azacitidine alone, researchers reported at the virtual annual meeting of the Society of Hematologic Oncology. The findings also showed that those who received the drug combo had a 79% overall response rate, compared with 57% ORR among those in the azacitidine only group.
Drug combo boosts EFS in higher-risk myelodysplastic syndrome
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.